Hereditary spastic paraplegia (HSP) due to ATP13A2 is a rare, inherited brain and spinal cord condition. It mainly causes stiffness and weakness in both legs. “Spastic” means the muscles are tight and hard to relax. “Paraplegia” means the problem affects the legs. “Hereditary” means it runs in families.

This subtype is called SPG78. It happens when both copies of the ATP13A2 gene have harmful changes (mutations). This gene makes a protein that sits in lysosomes. Lysosomes are tiny “recycling centers” inside cells. They break down waste and keep the cell clean. The ATP13A2 protein also helps control polyamines and ions in lysosomes. When ATP13A2 does not work, lysosomes fail. Waste builds up. Mitochondria (the cell’s “power plants”) can also suffer. Nerve cells in long motor pathways (corticospinal tracts) slowly get damaged. This leads to leg spasticity and other signs. PMC+2PMC+2y

ATP13A2-related HSP (SPG78) is a rare, inherited neurological condition in which damage to certain long nerve fibers in the spinal cord causes stiffness (spasticity) and weakness in the legs. The ATP13A2 gene helps cells move and recycle small molecules (polyamines) inside lysosomes, which are the cell’s recycling centers. When the gene does not work, polyamines can build up, harming lysosomes and mitochondria, and nerves gradually lose function. Many people develop spastic paraparesis first; some also show parkinsonism features (slowness, rigidity), gaze problems, or thinking changes over time. There is no cure yet; care focuses on spasticity relief, walking safety, and symptom control. PMC+4OUP Academic+4PMC+4

ATP13A2 disease was first recognized in families with juvenile parkinsonism called Kufor-Rakeb syndrome (PARK9). Later research showed the same gene can cause a form of complicated HSP named SPG78, reinforcing that ATP13A2 disorders sit on a spectrum from spasticity-predominant to parkinsonism-predominant. Most cases are autosomal recessive (both copies of the gene have variants). OUP Academic+3National Organization for Rare Disorders+3PMC+3

ATP13A2 normally exports polyamines from lysosomes to protect cells from oxidative stress and keep mitochondria healthy. When ATP13A2 is missing or faulty, polyamines accumulate in lysosomes, which can rupture and trigger nerve damage. New structural and mechanistic studies back this model and tie ATP13A2 to lysosome–autophagosome fusion and metal (Zn²⁺) homeostasis. These insights guide future therapy ideas but are not treatments yet. PMC+2PNAS+2

SPG78 is often a “complicated” form of HSP. “Complicated” means there can be extra features beyond leg spasticity, such as problems with balance (cerebellar signs), thinking (cognition), or movement features like parkinsonism in the ATP13A2 disease spectrum. PubMed+2PMC+2

ATP13A2 mutations were first known for Kufor-Rakeb syndrome (KRS), a juvenile parkinsonism (also called PARK9). Later, scientists found that ATP13A2 can also cause hereditary spastic paraplegia (SPG78) and neuronal ceroid lipofuscinosis (a lysosomal storage disease). This shows that the same gene can lead to different but related brain disorders that share lysosomal dysfunction. Frontiers+3PMC+3PubMed+3

---

Other names

• SPG78 (Spastic Paraplegia Type 78). This is the formal HSP label for ATP13A2-related HSP. PubMed+1

• ATP13A2-related HSP. A descriptive name used by clinicians. PubMed

• ATP13A2-associated neurodegeneration. A broad term that includes HSP, Parkinsonism (Kufor-Rakeb/PARK9), and NCL. Frontiers

• PARK9 disorders or Kufor-Rakeb spectrum (historically tied to ATP13A2; note that not all ATP13A2 patients have parkinsonism). NCBI+1

---

Types

Doctors group HSP into “pure” and “complicated” types. SPG78 is usually complicated HSP, meaning you see leg spasticity plus other neurologic features, such as balance problems, mild cognitive issues, or sometimes features along the ATP13A2 spectrum (e.g., parkinsonism). Onset can be in adulthood in several reports. PubMed+1

“Types” here does not mean many ATP13A2 subtypes. It means clinical patterns within SPG78:

1. Leg-predominant SPG78: Main problems are stiffness, slow walking, frequent tripping, and leg weakness. PubMed

2. SPG78 with cerebellar features: Add unsteady gait, limb clumsiness, and difficulty with fine movements. PubMed

3. SPG78 with cognitive features: Mild issues with attention, planning, or processing speed. PubMed

4. SPG78 within the ATP13A2 spectrum: Some families show partial overlap with parkinsonian signs (slow movements, rigidity) or other features in the same gene spectrum, even if full KRS criteria are not met. Frontiers

---

Causes

Because SPG78 is genetic, the single root cause is pathogenic variants in both ATP13A2 copies. Below are 20 mechanistic or risk-modifying causes and pathways that explain how and why nerve cells get sick. Each item is explained in very simple words.

1. Loss-of-function ATP13A2 variants (nonsense, frameshift, splice, severe missense) stop the protein from working. Lysosomes then fail to recycle waste well. OUP Academic

2. Defective lysosomal ion handling (e.g., K+ transport): ATP13A2 helps move ions across lysosomal membranes. Without this, the lysosome cannot keep the right internal balance. Nature

3. Faulty polyamine transport: ATP13A2 and other P5B-ATPases manage polyamines (like spermine). If polyamines pile up in lysosomes, they hurt cell function. PMC+1

4. Impaired autophagy: Autophagy is cell “self-cleaning.” ATP13A2 loss blocks the flow of autophagosomes to lysosomes, so damaged parts stay inside the cell. Nature

5. Mitochondrial stress: Mitochondria get fragmented and weak when lysosomes fail. Neurons then lack energy and are easier to injure. Nature

6. Toxic protein build-up: Poor lysosomal cleaning allows proteins to accumulate and harm neurons. PMC

7. α-synuclein sensitivity: While α-synuclein links are best known in Parkinson’s, ATP13A2 also protects against α-synuclein toxicity in lab models. Its loss may raise vulnerability. PubMed

8. Axonal degeneration in long tracts: The longest neurons (to the legs) are most sensitive to energy and transport problems, causing spastic paraparesis. (General HSP biology.) PMC

9. Neuroinflammation: Lysosomal failure and waste build-up can trigger inflammatory cascades that stress neurons further. (Mechanistic inference from lysosomal disease biology.) PMC

10. Endo-lysosomal pH imbalance: Wrong ion fluxes can shift lysosomal acidity and degrade enzymes’ function. Nature

11. Defective membrane trafficking: Lysosomes must fuse and move. ATP13A2 loss disturbs this, blocking normal recycling. PMC

12. Synaptic dysfunction: Sick axons and energy failure at synapses reduce signal strength to leg muscles. (HSP pathophysiology concept.) PMC

13. Lipid and waste accumulation: Storage material can collect when lysosomal enzymes cannot do their job well. (Seen across ATP13A2 disorders and NCL links.) Johns Hopkins University

14. Genetic background: Other variants may modify severity or add features (for example, interactions noted with LRRK2 carriers in PD genetics). Frontiers

15. Environmental stressors: In general neurodegeneration, toxins, infections, or trauma can unmask or worsen symptoms in vulnerable neurons (modifier, not primary driver). (General principle; ATP13A2 biology makes neurons less resilient.) PMC

16. Oxidative stress: Mitochondrial problems raise reactive oxygen species, which injure cells. Nature

17. Defective proteostasis: Cells cannot keep proteins folded and cleared properly without healthy lysosomes. PMC

18. Disturbed calcium and ion homeostasis: Lysosomal ion pumps help wider ion signaling; disruption stresses neurons. Nature

19. Age-related decline: Natural decline in cellular clean-up over time can speed up symptoms once ATP13A2 is impaired. (General neurodegeneration concept supported by lysosomal literature.) PMC

20. Cell-type vulnerability: Long corticospinal neurons are uniquely long and metabolically demanding, so ATP13A2 defects hit them harder, producing spastic legs first. (HSP core concept.) PMC

---

Symptoms

1. Stiff legs (spasticity): Leg muscles feel tight all the time. It is hard to bend the knee or ankle, and steps feel jerky. This is the hallmark of HSP. PMC

2. Weak legs (paraparesis): You can push less against resistance. Stairs feel heavy. Standing up takes effort. PMC

3. Slow, stiff walking (gait disturbance): The stride is short. Toes may catch the floor. You may scuff shoes quickly. PMC

4. Overactive reflexes (hyperreflexia): The doctor taps the tendon and gets a big, brisk response. PMC

5. Babinski sign: Stroking the foot makes the big toe go up. This shows corticospinal tract involvement. PMC

6. Falls or near-falls: Stiff legs and foot scuffing increase tripping, especially on uneven ground. PMC

7. Fatigue: Stiff walking costs more energy, so you tire faster. PMC

8. Leg cramps and spasms: Muscles may suddenly tighten, often at night or with exertion. PMC

9. Urinary urgency: You feel the need to urinate quickly due to spinal pathway involvement. PMC

10. Foot deformity (in some): High arch or toe issues can appear over time due to muscle imbalance. PMC

11. Balance problems (cerebellar signs in some): Unsteady gait and clumsy limb movements can occur in SPG78. PubMed

12. Mild cognitive issues (some patients): Planning, attention, or processing speed can be a little slower. PubMed

13. Slow movements or rigidity (rare overlap): Within the ATP13A2 spectrum, a few patients show parkinsonian features. Frontiers

14. Peripheral nerve features (occasionally): Some complicated HSPs show mild neuropathy, making feet numb or tingly. (Background HSP variability.) PMC

15. Speech or swallowing difficulty (rare in SPG78): If present, it is usually mild and part of a more complicated picture. (Complicated HSP concept; variable.) PMC

---

Diagnostic tests

A) Physical examination (bedside observation)

1. Gait assessment: The clinician watches how you walk. A stiff, scissoring, toe-dragging pattern suggests spastic paraparesis. PMC

2. Muscle tone testing: The doctor moves your legs passively. “Catch and release” resistance shows spasticity. PMC

3. Reflex testing: Very brisk knee and ankle jerks and an up-going big toe (Babinski) point to pyramidal tract involvement. PMC

4. Strength testing: Manual resistance checks show leg weakness, often hip flexors and ankle dorsiflexors. PMC

5. Cerebellar screen: Finger-to-nose and heel-to-shin tests reveal clumsiness if cerebellum is involved in SPG78. PubMed

B) Manual/functional tests (simple clinic tasks)

6. Timed 10-meter walk: You walk a set distance and time is recorded. It tracks gait speed over visits. (Standard HSP clinical measure.) PMC

7. Spasticity scales (e.g., Modified Ashworth Scale): The clinician grades muscle tone to monitor change. PMC

8. Functional balance tests (e.g., Tandem gait, Romberg): These reveal balance problems; tandem gait can be hard with cerebellar features. PubMed

9. Foot posture evaluation: Looks for high arches or toe deformities that come with long-standing spasticity. PMC

10. Bladder diary: Simple record of urinary urgency and frequency to document spinal pathway effects. PMC

C) Laboratory and pathological tests

11. Genetic testing for ATP13A2: The key test. A next-generation sequencing panel or whole-exome test looks for biallelic ATP13A2 variants confirming SPG78. OUP Academic

12. Variant classification (ACMG rules): The lab judges if each variant is pathogenic, likely pathogenic, or uncertain. This matters for counseling. (Standard genetics practice.) ScienceDirect

13. Metabolic screens (to rule out mimics): Basic blood tests (vitamin B12, copper, thyroid, etc.) make sure another treatable cause is not present. (General HSP work-up.) ScienceDirect

14. Research biomarkers: Studies examine lysosomal, polyamine, or mitochondrial markers as clues to ATP13A2 function; not yet routine in clinics. PMC

D) Electrodiagnostic tests

15. Nerve conduction studies (NCS): Check peripheral nerves. Often normal in pure HSP, but may show mild changes if neuropathy coexists. PMC

16. Electromyography (EMG): Looks for signs of muscle overactivity or denervation; helpful to exclude other neuromuscular diseases. PMC

17. Evoked potentials (e.g., motor evoked potentials): Measure conduction along the corticospinal tracts; can show slowing that matches clinical spasticity. ScienceDirect

E) Imaging tests

18. Brain MRI: May be normal or show mild corticospinal tract or cerebellar changes in complicated HSP like SPG78. It also excludes other causes. ScienceDirect

19. Spinal cord MRI: Rules out compression or other spinal diseases that mimic HSP and worsen spasticity. ScienceDirect

20. Advanced MRI markers (research): Some studies look at tractography to visualize long motor pathways; this is not standard but can aid research into HSP. ScienceDirect

Non-pharmacological treatments (therapies & others)

1. Individualized physiotherapy (stretch–strength–balance). A tailored program combines daily stretching to reduce muscle tightness, strengthening of hip and core, and balance and gait drills. Purpose: keep joints flexible, slow contractures, and improve safe walking. Mechanism: repeated stretching lowers reflex over-activity; strength and task-specific practice increase motor unit recruitment and postural control. Evidence in HSP shows PT can reduce spasticity and improve lower-limb strength and function. Frontiers+1

2. Gait training on treadmill or instrumented walkways. Supervised walking with visual targets or obstacle stepping trains adaptability. Purpose: safer steps, fewer trips. Mechanism: repetitive stepping rewires spinal and cortical circuits (practice-based neuroplasticity). Trials in HSP are underway to individualize gait rehabilitation. BioMed Central

3. Robot-assisted or body-weight–supported gait. Harness support or robotic legs let people practice longer with proper patterns. Purpose: build endurance and symmetry without over-fatigue. Mechanism: high-repetition stepping shapes central pattern generators. Reviews suggest potential benefit for spastic gait. PMC

4. Hydrotherapy. Warm water reduces gravity load and spasm, enabling longer stretches and smoother stepping. Purpose: pain relief, joint range, confidence. Mechanism: buoyancy and warmth dampen stretch reflexes and allow active ROM. HSP rehab reviews include hydrotherapy among promising options. PMC

5. Functional electrical stimulation (FES). Small surface electrodes stimulate weak muscles (e.g., ankle dorsiflexors) during gait. Purpose: lift the toes, reduce tripping. Mechanism: timed stimulation assists movement and may reduce co-contraction. HSP summaries list electrostimulation as potentially helpful. PMC

6. Ankle-foot orthoses (AFOs). Light braces keep the ankle neutral, limit plantarflexor spasticity, and improve toe clearance. Purpose: steadier steps and fewer falls. Mechanism: mechanical alignment reduces spastic triggers and energy cost. HSP management guidelines recommend orthoses for gait safety. Frontiers

7. Assistive devices (cane, walker, trekking poles). A correctly fitted device widens your base and shares load with the arms. Purpose: immediate fall risk reduction. Mechanism: external support reduces sway and compensates for hip adductor spasticity. General HSP care emphasizes practical aids. NINDS

8. Task-oriented balance training & fall-prevention classes (e.g., tai chi). Purpose: improve reactive balance and confidence. Mechanism: practice under varied conditions strengthens sensory integration and stepping responses. National fall-prevention guidance supports structured balance programs in adults. Verywell Health

9. Spasticity self-management (daily home program). Gentle, twice-daily hamstring/calf/adductor stretches held 30–60 seconds; heat before, ice after if sore. Purpose: sustain clinic gains. Mechanism: reduces muscle spindle sensitivity over time. HSP care frameworks stress daily routines. Frontiers

10. Occupational therapy (energy conservation & ADL strategies). Purpose: make dressing, bathing, and transfers simpler and safer. Mechanism: adaptive tools and task modification cut effort and spasm triggers. HSP management reviews highlight OT for independence. Frontiers

11. Botulinum toxin care pathway (with therapy). For focal overactive muscles (e.g., hip adductors), BoNT-A reduces tone; therapy then retrains movement. Purpose: easier hygiene, better step width. Mechanism: blocks acetylcholine at the neuromuscular junction for ~3 months. Guidelines and systematic reviews support BoNT-A for adult limb spasticity. rcp.ac.uk+2American Academy of Family Physicians+2

12. Serial casting & splinting. Repeated casts or night splints gradually lengthen tight tendons. Purpose: delay surgery. Mechanism: low-load, long-duration stretch remodels muscle-tendon units. Used within spasticity pathways alongside therapy. rcp.ac.uk

13. Pain management without drugs (heat, massage, mindfulness). Purpose: reduce pain that amplifies spasm. Mechanism: heat increases tissue extensibility; relaxation lowers sympathetic drive. Included in spasticity guidelines as adjuncts. rcp.ac.uk

14. Home safety optimization. Remove loose rugs, add grab bars, improve lighting, use non-slip footwear. Purpose: fewer slips/trips. Mechanism: reduces environmental hazards that interact with spastic gait. Fall-prevention guidance endorses this. Verywell Health

15. Nutrition & hydration plan. Adequate protein and fiber support muscle and bowel function; hydration helps reduce cramps. Purpose: maintain energy and prevent complications of immobility. Mechanism: supports neuromuscular function and GI motility. General HSP education materials recommend holistic care. NINDS

16. Bladder and bowel routines. Timed voiding, pelvic-floor training, stool-softening diet. Purpose: reduce urgency and constipation that can worsen spasticity. Mechanism: lowers autonomic triggers. HSP overviews list autonomic symptoms management in care plans. NINDS

17. Psychological support & fatigue pacing. Counseling and pacing plans prevent boom-and-bust cycles. Purpose: preserve participation and mood. Mechanism: reduces stress-related tone increases and improves adherence. HSP care is long-term and benefits from psychosocial support. NINDS

18. Community exercise (walking groups, dancing). Purpose: social support, cardiovascular fitness, and mobility. Mechanism: repetition + enjoyment sustain adherence; balance elements reduce falls. Public health guidance supports structured group activity for fall risk. Verywell Health

19. Shock-wave therapy (selected centers). Some studies report tone reduction after extracorporeal shock wave therapy. Purpose: adjunct for stubborn focal spasticity. Mechanism: may modulate neuromuscular reflexes and tissue stiffness. Evidence is emerging and mixed; discuss locally. Lippincott Journals

20. Intrathecal baclofen evaluation (non-oral option). For severe, generalized spasticity not controlled with tablets, a test dose can predict response to a programmable pump. Purpose: reduce whole-body tone with fewer systemic side effects. Mechanism: delivers baclofen into CSF at the spinal level to inhibit reflex arcs. HSP case series show improved tone and function for years in suitable patients. PMC+1

---

Drug treatments

1. Carbidopa/Levodopa (IR; e.g., Sinemet/Dhivy). Class: dopamine precursor + decarboxylase inhibitor. Dose often starts low multiple times daily and is titrated. Purpose: treats parkinsonian slowness/rigidity when present in ATP13A2 disease. Mechanism: levodopa converts to dopamine in the brain; carbidopa reduces nausea and peripheral conversion. Side-effects: nausea, low blood pressure, dyskinesia with higher/long use; avoid non-selective MAOIs. FDA Access Data+1

2. Carbidopa/Levodopa (ER + IR mix; CREXONT). Class: dual-release levodopa system. Dose: individualized granules/pellets regimen. Purpose: smooth “ON” time, reduce wearing-off. Mechanism: immediate + extended levodopa delivery. Side-effects: similar to IR; counsel on GI and hypotension risks. FDA Access Data

3. Levodopa/Carbidopa intestinal infusion (e.g., VYALEV). Class: continuous jejunal levodopa/carbidopa via pump. Purpose: for significant motor fluctuations. Mechanism: steady dopamine levels reduce OFF time. Side-effects: device/pump complications, dyskinesia, hypotension; plan oral backup for interruptions. FDA Access Data

4. Baclofen (oral solutions/granules). Class: GABA-B agonist antispastic. Dose: start low, divided doses; taper to stop. Purpose: reduces generalized spasticity and cramps. Mechanism: dampens spinal reflex arcs. Side-effects: sleepiness, weakness; abrupt stop may cause withdrawal. FDA Access Data+1

5. Tizanidine. Class: α2-adrenergic agonist antispastic. Dose: titrate in divided doses; be consistent with/without food. Purpose: reduces muscle tone and spasms. Mechanism: lowers excitatory neurotransmission in spinal interneurons. Side-effects: hypotension, sedation; major CYP1A2 interactions (e.g., ciprofloxacin). FDA Access Data

6. Dantrolene. Class: direct skeletal muscle relaxant. Dose: titrated oral; monitor liver function. Purpose: reduces refractory spasticity when others fail. Mechanism: reduces calcium release from sarcoplasmic reticulum. Side-effects: hepatotoxicity risk; weakness. FDA Access Data

7. OnabotulinumtoxinA (BOTOX). Class: acetylcholine release inhibitor (local injection). Dose: individualized by muscle every ~12 weeks. Purpose: focal tone reduction (e.g., hip adductors, gastrocnemius) to improve hygiene, step width, brace fit. Side-effects: injection-site pain, transient weakness; systemic spread is rare. FDA Access Data

8. Amantadine (IR or ER—Gocovri). Class: dopaminergic + NMDA modulation. Dose: daily (ER) or BID (IR), renal adjust. Purpose: can help fatigue, dyskinesia, or mild parkinsonism. Side-effects: hallucinations, edema, livedo reticularis, dizziness. FDA Access Data+1

9. Selegiline (Eldepryl/Zelapar ODT). Class: MAO-B inhibitor. Dose: typically 5–10 mg/day (formulation-specific). Purpose: mild symptomatic benefit and “ON” extension with levodopa. Side-effects: insomnia, interactions at high/non-selective doses. FDA Access Data+1

10. Rasagiline (Azilect). Class: MAO-B inhibitor. Dose: 0.5–1 mg daily—do not exceed recommended dose to avoid non-selective MAO effects. Purpose: smoothes motor fluctuations. Side-effects: serotonin risk with certain drugs, hypertensive crisis above target doses. FDA Access Data+1

11. Safinamide (Xadago). Class: reversible selective MAO-B inhibitor with glutamatergic effects. Dose: 50–100 mg daily as levodopa add-on. Purpose: increases daily “ON” time without troublesome dyskinesia. Side-effects: dyskinesia, nausea, insomnia; drug interaction checks needed. FDA Access Data+1

12. Pramipexole (IR/ER). Class: dopamine agonist. Dose: titrate slowly; adjust in kidney disease. Purpose: treats parkinsonian features when present. Side-effects: sleepiness, impulse-control disorders, edema; rare rhabdomyolysis reports. FDA Access Data+1

13. Ropinirole (IR/XL). Class: dopamine agonist. Dose: gradual weekly titration. Purpose: similar to pramipexole—levodopa-sparing in some. Side-effects: nausea, dizziness, impulse-control issues; taper to stop. FDA Access Data+1

14. Entacapone (Comtan). Class: COMT inhibitor add-on to levodopa. Dose: 200 mg with each levodopa dose (max frequency per label). Purpose: prolongs levodopa effect; reduces wearing-off. Side-effects: diarrhea, brownish urine, dyskinesia increase. FDA Access Data+1

15. Opicapone (Ongentys). Class: once-daily COMT inhibitor. Dose: usually 50 mg at bedtime; avoid in severe hepatic disease. Purpose: extends levodopa “ON” time. Side-effects: dyskinesia, constipation, insomnia. FDA Access Data+1

16. Tolcapone (Tasmar). Class: COMT inhibitor. Dose: TID; reserved due to liver toxicity risk. Purpose: powerful wearing-off reduction if monitored. Side-effects: serious hepatotoxicity—requires strict LFT monitoring. FDA Access Data+1

17. Trihexyphenidyl (Artane). Class: anticholinergic. Dose: small divided doses, mostly for tremor/dystonia in younger adults. Purpose: can ease dystonia/rigidity but limited by side-effects. Side-effects: dry mouth, constipation, confusion—use cautiously. FDA Access Data+1

18. Clonazepam. Class: benzodiazepine. Dose: bedtime or divided small doses. Purpose: can help nocturnal spasms, myoclonus, or anxiety; not first-line for daytime tone. Side-effects: sedation, dependence; taper to stop. FDA Access Data

19. Intrathecal Baclofen (pump medication). Class: GABA-B agonist delivered into CSF. Dose: programmable micro-infusion after positive test dose. Purpose: strong reduction in severe generalized spasticity with fewer systemic effects vs oral. Side-effects: pump/catheter issues; withdrawal if abruptly stopped. PMC

20. OnabotulinumtoxinA (focal regimen) with therapy reinforcement. Listed again here because dosing is drug-specific and not interchangeable; individualized muscle maps and repeat cycles are standard. Purpose/Mechanism/Effects as above; combine with stretching and task practice to lock in gains. FDA Access Data+1

Notes: Drug choices depend on your symptom mix (spasticity-predominant vs parkinsonism-predominant). No medication is proven to stop progression in ATP13A2-HSP; treatments are symptom-targeted. Always discuss interactions (e.g., MAO-B inhibitors + other serotonergic drugs). NINDS

---

Dietary molecular supplements

1. Coenzyme Q10 (CoQ10). Typical study doses: 300–1200 mg/day. Function: mitochondrial electron carrier and antioxidant. Mechanism: supports ATP production and reduces oxidative stress. Evidence: human PD trials/meta-analyses largely negative for motor progression, though precision-medicine approaches are being explored. PMC+2PubMed+2

2. Vitamin D3. Study doses vary (e.g., 800–2000 IU/day) with individualized targets. Function: bone/muscle health, possibly balance. Mechanism: nuclear receptor signaling in muscle and neurons. Evidence: meta-analyses show inconsistent motor benefits in PD; prioritize correcting documented deficiency for bone and fall risk. PMC+1

3. Omega-3 (EPA/DHA). Study ranges ~1–2 g/day combined. Function: anti-inflammatory lipid support; mood benefits. Mechanism: membrane fluidity, eicosanoid balance. Evidence: limited RCTs suggest adjunct symptom benefits; more trials needed. ScienceDirect+1

4. N-Acetylcysteine (NAC). Study doses: 1200–2400 mg/day oral (varied). Function: glutathione precursor. Mechanism: antioxidant replenishment; possible dopaminergic support. Evidence: small studies show DAT signal and symptom improvements; confirmatory trials pending. PMC+1

5. Creatine monohydrate. Study doses: 5–10 g/day. Function: energy buffer. Mechanism: phosphocreatine system support. Evidence: large long-term PD trial showed no disease-slowing effect; may aid fatigue/mood in some. PMC+1

6. Vitamin B12. Doses: repletion if low per labs. Function: nerve myelin support. Mechanism: methylation pathways. Evidence: low B12 linked to falls in parkinsonism; correct deficiency rather than empiric megadosing. ScienceDirect

7. Alpha-lipoic acid. Doses: 300–600 mg/day in studies. Function: antioxidant cofactor. Mechanism: regenerates other antioxidants; chelates metals. Evidence: supportive in oxidative stress models; clinical PD data limited. Frontiers

8. L-carnitine/Acetyl-L-carnitine. Doses: 1–2 g/day. Function: mitochondrial fatty-acid transport. Mechanism: improves energy handling; possible neurotrophic effects. Evidence: mixed; consider only with clinician guidance. Frontiers

9. Curcumin. Doses: varied, often 500–1000 mg/day (enhanced bioavailability forms). Function: anti-inflammatory/antioxidant. Mechanism: NF-κB and oxidative stress modulation. Evidence: promising preclinical signals; human PD data limited. Frontiers

10. Magnesium (glycinate/citrate). Doses: diet-guided; avoid excess. Function: muscle/nerve excitability regulation. Mechanism: NMDA modulation. Evidence: theoretical benefit for cramps/spasm; robust HSP data lacking—use only for documented deficiency. Frontiers

---

Immunity-booster / regenerative / stem cell” drug approaches

1. Intrathecal mesenchymal stem cell (MSC) therapy. Small studies in spasticity and other neuro conditions explore CSF delivery to modulate inflammation and trophic support. Status: investigational; no HSP approvals; risks include procedure complications. ScienceDirect

2. Neurotrophic factor strategies (e.g., GDNF pathways). Aim to support dopamine neurons or corticospinal tracts. Status: mixed PD trial results; not available for ATP13A2-HSP. NINDS

3. Exosome-based therapies. MSC exosomes investigated to deliver protective RNAs/proteins. Status: preclinical/early clinical only; unproven in HSP. Frontiers

4. Gene-targeted therapy for ATP13A2. Concept: restore lysosomal polyamine export. Status: preclinical; mechanistic studies mapping transporter structure and function inform future vectors. ScienceDirect+1

5. Erythropoietin or related agents (neurotrophic effects). Studied for neuroprotection in other disorders; not standard for HSP. Status: experimental only. NINDS

6. Immunomodulators (broad). Because ATP13A2-HSP is not autoimmune, routine immunosuppression has no established role; avoid off-label use outside trials. Status: not recommended. Frontiers

Important: Be cautious with private “stem-cell clinics.” Seek care only within regulated clinical trials. Frontiers

---

Surgeries

1. Intrathecal Baclofen (ITB) pump implantation. A catheter delivers baclofen into your spinal fluid from a small pump under the skin. Why: severe, generalized spasticity not controlled with tablets. Evidence in HSP shows tone reduction and mobility stabilization for years in responders. PMC

2. Selective peripheral neurectomy or neurotomy (focal). Surgeons partially cut overactive motor nerve branches to very spastic muscles. Why: durable focal tone relief when BoNT and therapy are insufficient. Reviews show good results in selected adults. PMC

3. Tendon lengthening (e.g., hamstrings, Achilles) and soft-tissue releases. Why: fixed contractures that block brace fit or gait. Mechanism: increases range, eases bracing/walking. Orthopedic literature supports lengthening/transfer procedures for spastic deformities. rimed.org

4. Tendon transfers/joint stabilization. Move tendon force to balance joints (e.g., foot inversion). Why: improve foot clearance or hand use when spastic patterns are fixed. PMC

5. Deep Brain Stimulation (DBS) (selected cases with marked parkinsonism). Electrodes in STN or GPi modulate circuits. Why: levodopa-responsive parkinsonism with fluctuations/dyskinesia—case reports include ATP13A2 spectrum; role remains uncertain. PMC+1

---

Preventions

1. Fall-proof the home: remove clutter/rugs, add grab bars, good lighting. Verywell Health

2. Daily stretch routine to prevent contractures and reduce tone surges. Frontiers

3. Consistent footwear & AFOs for toe clearance and stability. Frontiers

4. Balance classes (tai chi/dance) to improve reactive balance. Verywell Health

5. Hydration and fiber to prevent constipation-triggered spasms. NINDS

6. Medication schedule adherence (e.g., MAO-B/levodopa timings). FDA Access Data

7. Vision checks and assistive devices tuned by PT/OT. NINDS

8. Skin checks/pressure relief if mobility is reduced. NINDS

9. Bone health labs (vitamin D/B12) and strength training for fall risk. PMC+1

10. Vaccinations & infection precautions to avoid illness-related setbacks. NINDS

---

When to see doctors

• New or worsening falls, severe spasms, or painful contractures affecting walking or sleep. These may need medication changes, BoNT, or AFO adjustments. rcp.ac.uk

• Parkinsonian symptoms (slowness, rigidity, tremor) appearing or changing—levodopa/adjuncts may help. NINDS

• Pump or device issues (ITB alarms, sudden stiffness—possible withdrawal). Urgent evaluation is required. PMC

• Mood, anxiety, or fatigue that reduces participation—treatable and impactful on function. NINDS

• Swallowing, bladder, or bowel changes—optimize routines and rule out infections. NINDS

---

What to eat & what to avoid

1. Aim for a Mediterranean-style plate: vegetables, legumes, whole grains, fish, nuts, olive oil. Supports general brain and heart health. Wiley Online Library

2. Protein timing with levodopa: if you use levodopa, take doses away from large protein meals to improve absorption (clinician advice applies). FDA Access Data

3. Stay hydrated (water, herbal teas) to reduce cramps and constipation. NINDS

4. Include omega-3 sources (fatty fish, flax, walnuts) 2–3 times/week. Wiley Online Library

5. Keep vitamin D/B12 adequate (food first; supplement only if low per labs). PMC

6. Plenty of fiber (25–30 g/day) from plants for bowel regularity. NINDS

7. Limit ultra-processed foods and added sugars that worsen energy swings. Wiley Online Library

8. Alcohol only in moderation—can worsen balance and sleep. Verywell Health

9. Caffeine: small amounts may help alertness; avoid late-day if sleep is poor. NINDS

10. Discuss supplements with your clinician—evidence varies and interactions happen (e.g., with MAO-B inhibitors). FDA Access Data

---

FAQs

1. Is ATP13A2-HSP the same as Kufor-Rakeb syndrome? They share the same gene; presentations range from spasticity-dominant (SPG78) to parkinsonism-dominant (KRS). OUP Academic+1

2. Is there a cure? Not yet. Treatments target symptoms, safety, and quality of life. Frontiers

3. Will exercise make it worse? No—well-planned therapy helps mobility and spasticity. PMC

4. Can levodopa help? If parkinsonism features are present, levodopa or MAO-B inhibitors may improve movement. FDA Access Data+1

5. What if tablets cause sleepiness? Dose timing and options (e.g., BoNT for focal tone, ITB for generalized tone) can reduce systemic side-effects. rcp.ac.uk+1

6. Are stem cells available in clinics? Only in research settings; no approved stem-cell therapy for HSP—avoid unregulated clinics. Frontiers

7. Will braces weaken my legs? Properly prescribed AFOs support safer walking and reduce falls while you continue strengthening. Frontiers

8. Does Botox “paralyze” the muscle forever? No—effects last ~3 months and are localized; combine with therapy to improve function. FDA Access Data

9. Can diet fix HSP? No; but a balanced, anti-inflammatory pattern can support energy and reduce comorbid risks. Wiley Online Library

10. Which supplement is best? None has proven disease-modifying benefit; correct deficiencies (D/B12) and consider others only with your clinician. PMC

11. Why do I trip? Hip adductor and calf spasticity shorten steps and reduce toe clearance; therapy/AFOs/BoNT can target this. rcp.ac.uk

12. Is surgery permanent? Soft-tissue procedures and neurotomies aim for durable tone/contracture relief; outcomes depend on goals and rehab. PMC

13. Can DBS help ATP13A2 disease? Rare case reports suggest benefit for severe parkinsonism, but the role is uncertain. PMC

14. What about fatigue? Pacing, sleep optimization, mood support, and careful med timing are key. NINDS

15. What specialists should I see? Neurology (movement disorders), physiatry (spasticity), PT/OT, orthopedics/spasticity surgery, and genetics for counseling. Frontiers

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.